Peter Lynch · Growth at a reasonable price (GARP)
Is Royalty Pharma plc (RPRX) a Peter Lynch Stock?
Some GARP characteristics, but growth or valuation is stretched.
58/100
Mixed
2/6 criteria passed
Peter Lynch's Criteria, Applied to RPRX
PEG ≤ 1.0
key2.33
EPS CAGR ≥ 15%
key11.8%
Revenue CAGR ≥ 10%
1.0%
Net margin > 0
33.9%
How RPRX Scores on Other Strategies
Live Financial Snapshot
Market cap
$38.1B
P/E (TTM)
27.6x
ROIC (TTM)
8.43%
Gross margin
99.95%
Other Peter Lynch fit reports
Frequently Asked Questions
What is RPRX's Peter Lynch fit score?
RPRX scores 58/100 on our Peter Lynch fit engine. Some GARP characteristics, but growth or valuation is stretched.
Does Peter Lynch actually own RPRX?
Our score is computed from financial fundamentals against Peter Lynch's published criteria. We don't claim that Peter Lynch personally owns or recommends RPRX.
How often is this score updated?
RPRX's Peter Lynch fit score is recomputed daily from the latest TTM financials. The page below shows when it was last refreshed.
Educational tool, not investment advice. Scores are computed from publicly-available financial data against published investing-strategy criteria. We do not claim that Peter Lynch personally owns or recommends RPRX.
